Addex Therapeutics

Addex Therapeutics Dividend Coverage

Dividend Coverage Ratio of Addex Therapeutics (ADXN) as of Oct 21, 2026.

Dividend Coverage

-

Last updated:

Dividend Coverage Ratio of Addex Therapeutics is 2026 - . Dividend Coverage Ratio of Addex Therapeutics was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Addex Therapeutics Stock analysis

What does Addex Therapeutics do? Addex Therapeutics Ltd, based in Geneva, Switzerland, discovers and develops small-molecule pharmaceuticals targeting neurological disorders. The company focuses on G-protein coupled receptors and enzymes, with lead programs including Dipraglurant in Phase 1 for post-stroke/TBI recovery and Parkinson's disease, and ADX71149 in Phase 1 for undisclosed indications. It collaborates with Janssen Pharmaceuticals and Indivior PLC for GABAB PAM compounds addressing pain, anxiety, addiction, and other central nervous system conditions. Addex Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Addex Therapeutics stock

On Eulerpool you can find the complete historical development of Dividend Coverage Ratio Addex Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The dividend coverage ratio measures how many times dividends can be covered by net income. Higher coverage suggests more sustainable dividend payments.

Dividend Coverage Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Coverage Ratio's Addex Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — Addex Therapeutics

All Key Metrics — Addex Therapeutics